Trials / Terminated
TerminatedNCT04026750
Insulin Tolerance Test Study in Patients With Type 1 Diabetes
A Randomized, Double-Blind, Placebo-Controlled Insulin Tolerance Test Study to Assess the Safety, Tolerability, and Pharmacodynamics OF Pitolisant in Patients With Type 1 Diabetes
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- High Point Clinical Trials Center · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the safety, tolerability and pharmacodynamics of pitolisant in patients with Type 1 Diabetes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pitolisant | Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated. |
Timeline
- Start date
- 2019-09-15
- Primary completion
- 2020-02-16
- Completion
- 2020-02-16
- First posted
- 2019-07-19
- Last updated
- 2021-04-02
- Results posted
- 2021-04-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04026750. Inclusion in this directory is not an endorsement.